Thymosin Alpha-1

Thymosin Alpha-1 (Tα1, also called thymalfasin and sold as Zadaxin) is a 28-amino-acid peptide derived from the thymus gland, originally isolated from calf thymus extract in the 1970s ¹². The body produces small amounts naturally from a precursor called prothymosin alpha, and circulating levels fall in several chronic disease states ²⁸.

Unlike most research peptides, Tα1 carries roughly four decades of human clinical data across hepatitis, oncology, and critical care ². It works as a biological response modifier: it helps immature immune cells mature, boosts natural killer (NK) and dendritic cell function, and tilts the response toward the T helper 1 (Th1) arm ¹. The net effect is immune normalization rather than blunt stimulation, strengthening responses where they are weak and restraining inflammation where it is excessive ¹¹.

The most-studied indications include chronic hepatitis B, sepsis and critical illness, acute COPD exacerbations, and adjunctive cancer care ¹. Tα1 is registered for chronic hepatitis B in several countries, though not in the United States ¹¹.

Tα1 works on the immune system's trainers: dendritic cells (DCs), the cells that teach T cells which threats to attack. On human dendritic cells, Tα1 raises co-stimulatory molecules such as CD40 and CD80 while reducing the inhibitory signal PD-L1, strengthening antigen presentation ³⁵. It also activates innate immune signaling through the toll-like receptor (TLR) pathway, including IKK and MAPK cascades ³⁴.

A recently defined step happens inside the dendritic cell ²⁴. Tα1 binds a small RNA molecule (miR-146a-5p) carried on fragments of dying tumor cells and protects it from degradation in the cell's lysosome. The stabilized RNA then activates TLR7, the sensor that licenses the dendritic cell to mature, migrate to lymph nodes, and present tumor antigens to CD8+ T cells ²⁴.

Downstream effects

• T-cell maturation and exhaustion reversal: Tα1 promotes Th1 polarization and, with co-stimulation, increases CD8+ T-cell proliferation and effector cytokines while reducing the exhaustion markers PD-1, TIM-3, and LAG-3 ¹.
• Macrophage repolarization: Tα1 shifts tumor-supporting M2 macrophages toward an antitumor phenotype, an effect that depends on CD8+ T cells ³⁷.
• MDSC blockade: Tα1 suppresses tumor VEGF and HIF-1α, blocking the migration of myeloid-derived suppressor cells into the tumor microenvironment ³⁸.
• Direct neuroprotection: Tα1 engages the orexin receptor HCRTR1 on neurons, suppressing the cell-death pathway called necroptosis; circulating Tα1 is low in stroke patients in proportion to severity ²⁵.

The parent peptide clears from the blood in about three hours, but the immune-cell changes it sets in motion persist for days, which is why study schedules use twice- or thrice-weekly dosing ¹.

Documented effects with Tα1 track strongly with the indication studied. The strongest signals come from infection and critical-care settings, where meta-analyses of human trials exist.

In meta-analyses of randomized trials

• Sepsis: across 1,972 patients, Tα1 lowered 28-day mortality (RR 0.77) and ICU mortality, and reduced time on mechanical ventilation ⁵. A network meta-analysis ranked Tα1 plus ulinastatin among the top regimens for mortality (RR 0.65) ⁴. In the phase 3 Reset-α trial, Tα1 reduced the organ-failure score SOFA by 3.5 points versus 1.13 for placebo ⁶.
• Chronic hepatitis B: a Cochrane review of 10 trials (1,349 participants) found Tα1 may reduce all-cause mortality (RR 0.53) and HBV-related mortality, with fewer serious adverse events than control; certainty was graded very low ².
• COPD exacerbations: a meta-analysis of 39 trials (3,329 patients) reported improved lung function, higher oxygen levels, and shorter hospital stays ⁹.
• Severe acute pancreatitis: across 706 patients, Tα1 cut extrapancreatic infections (RR 0.56) and improved the CD4/CD8 ratio ¹⁹.

In cancer care

Oncology data are largely observational and concentrated in Chinese cohorts ¹. In the phase 2 PRaG 5.0 trial of heavily pretreated solid tumors, adding Tα1 to a PD-1 inhibitor, radiotherapy, and GM-CSF produced a 30.8% objective response rate with no grade 3 or higher treatment-related events ³. In a randomized phase 2 melanoma trial (n=483), the 3.2 mg Tα1 arms produced 13 and 10 confirmed responses versus 5 in the control arm ¹⁴. Observational liver-cancer reports show improved recurrence-free survival when Tα1 is added to anti-PD-1 therapy (98.4% versus 49.2% at one year) ¹⁷, though these designs require prospective confirmation ¹.

Other documented signals

• Severe COVID-19 cohorts conflict: one reported mortality of 11.1% with Tα1 versus 30% in controls among patients with low T-cell counts ³⁰, while a larger multicenter cohort linked Tα1 to worse recovery when started late ³¹.
• A small open-label pilot in immunodeficient patients with depression (n=5) found depressive scores fell roughly 52% on an 8-week course ⁸.
• In hemodialysis patients, Tα1 improved antibody responses to pandemic H1N1 influenza vaccine ²⁹.
• Tα1 improved frozen-embryo-transfer outcomes in a small self-controlled cohort (implantation rate 63.4%) ⁶⁰.

What has not been shown

No large randomized trial supports generalized anti-aging or longevity claims; evidence for those uses remains anecdotal or mechanistic ¹¹.

Nearly all published Tα1 research uses subcutaneous injection at a fixed 1.6 mg adult dose, without body-weight adjustment ¹. Schedules vary by indication, and essentially every study design is course-based rather than continuous ².

Schedule patterns from studies

• Chronic hepatitis B: 1.6 mg twice weekly for 6 to 12 months in the pooled Cochrane trials ², with a 6-month randomized trial using the same twice-weekly schedule ⁴⁷.
• Sepsis (acute critical illness): 3.2 mg (two 1.6 mg vials) twice daily for 7 days with standard care in the phase 3 Reset-α trial ⁶.
• Cancer adjunct: 1.6 mg two to three times weekly, aligned with chemotherapy, radiotherapy, or checkpoint-inhibitor cycles ¹. The PRaG 5.0 phase 2 protocol adds a 7-day daily loading phase when baseline T-cell counts are low, then 1.6 mg three times weekly ³.
• Metastatic melanoma dose-finding: 1.6, 3.2, or 6.4 mg on days 8-11 and 15-18 of 28-day cycles; the 3.2 mg level performed best ¹⁴.
• Community immune-support use: 1.6 mg twice weekly in 4-8 week blocks, sometimes preceded by a 5-7 day daily loading phase during acute immune stress, consistent with published loading schemes ³.

Dosing is flat rather than weight-scaled across adult cohorts. The 6.4 mg level has been tolerated in trials, and higher-dose sepsis regimens are reserved for supervised hospital care ⁶. Endogenous Tα1 peaks shortly after light onset in mice, and morning administration is the common community convention, though no human trial has compared timing ⁴⁹.

Thymosin Alpha-1 is supplied as a freeze-dried (lyophilized) powder that must be dissolved before use. The standard diluent is bacteriostatic water containing 0.9% benzyl alcohol; pre-filled 1.6 mg clinical vials remove the dilution step in trial settings, and a 2025 expert consensus provides standardized application guidance ¹.

To reconstitute, direct the diluent down the inside wall of the vial and roll gently to dissolve the powder; shaking can denature the peptide. This page's calculator handles the volume and concentration math for common vial sizes.

Storage

• Lyophilized powder: refrigerated or frozen for long-term storage, protected from light.
• Reconstituted solution: keep at 2-8°C and use within about 14 days.
• Freeze-thaw: avoid repeating it with reconstituted solution; if freezing is required, aliquot single doses first.

The parent peptide's roughly 3-hour plasma half-life underlies the twice-weekly dosing schedule used across studies ¹. Research-grade half-life extensions include N-terminal PEGylation ⁶⁴ and an IgG1 CH3 fusion reaching 47 hours ²⁷; investigational liquid-crystal depots sustain in vitro release for up to two weeks ⁴².

Most Tα1 interaction data come from combination studies rather than dedicated drug-interaction trials, since the peptide is almost always studied as an add-on ¹. No formal pharmacokinetic interaction studies exist ⁷.

Combinations with published human data

• Checkpoint inhibitors: adding Tα1 to anti-PD-1 therapy improved median survival in unresectable liver cancer (16 versus 11 months) ¹⁶ and recurrence-free survival in adjuvant HCC (HR 0.174) ¹⁷. The PRaG platform combined Tα1 with a PD-1 inhibitor, radiotherapy, and GM-CSF with no grade 3 or higher treatment-related events ³. One case of severe multisystem immune-related toxicity has been reported with sintilimab plus Tα1, so combination use merits close monitoring ²³.
• Chemotherapy: in a randomized phase 2 melanoma trial, Tα1 plus dacarbazine produced more confirmed responses than chemotherapy alone, with no added toxicity ¹⁴. Mechanistically, Tα1 binds fragments of dying tumor cells released by chemotherapy to activate dendritic-cell training ²⁴.
• Hepatitis B antivirals: a meta-analysis found entecavir plus Tα1 produced higher complete-response rates than entecavir alone (RR 1.18) with fewer adverse events ⁵⁶; the Cochrane review found no interaction by co-intervention across ten trials ².
• Antifungals: voriconazole plus Tα1 improved clinical efficacy (96% versus 80%) and fungal clearance in COPD-associated invasive aspergillosis ²¹.
• Sepsis adjuncts: in a 76-trial network meta-analysis, ulinastatin plus Tα1 reduced mortality (RR 0.65) and ventilation time ⁴.
• Vaccines: Tα1 enhanced H1N1 vaccine responses in hemodialysis patients ²⁹ and has been tested as prophylaxis in dialysis patients during COVID-19 ⁴⁵.

Theoretical cautions

Rat data show Tα1 inhibits both intrinsic and extrinsic blood-coagulation pathways, raising a question about anticoagulant combinations that has not produced any human bleeding signal ⁵¹. In vitro, Tα1 inhibits angiotensin-converting enzyme ⁵⁷. Central administration in rats shifts TSH, ACTH, and prolactin release, an endocrine axis worth monitoring when combining Tα1 with thyroid or adrenal therapies ⁵³.

Peptide combinations

Tα1 and Thymosin Beta-4 pull on opposite immune levers in the mixed lymphocyte reaction, so community practice avoids stacking them for immune endpoints ⁶¹. Investigational synergy has been reported with IL-15 against senescent CD8+ T cells in liver-cancer models ⁶².

Tα1 is studied in courses rather than continuously across essentially every trial design ². Duration follows the indication: 7 days in acute sepsis ⁶, 8 weeks in vaccine and immune-recovery protocols ²⁹, 6 months in chronic hepatitis B ², and until progression in oncology maintenance ³.

Why courses rather than continuous dosing

Tα1 produces population-level immune changes (thymic output, T-cell maturation, reversal of exhaustion markers) that develop over weeks and outlast the short-lived circulating peptide ³. Because the model is replenishment rather than continuous receptor activation, study designs are built around treatment windows followed by assessment.

Community cycling practice

For general immune-support use outside formal indications, common practice is a 4-8 week course of 1.6 mg twice weekly, sometimes with a 5-7 day daily loading phase, followed by 2-4 weeks off, with repeat courses as needed. This mirrors the 8-week treatment window used in dialysis vaccine and CVID studies ⁸.

What the washout data show

The clearest evidence that effects depend on continued dosing comes from the CVID pilot: immune-cell gains present at week 8 were not sustained 8 weeks after the last injection, and depressive symptoms partially recurred in the most severe patients ⁸. No rebound or withdrawal phenomenon has been described across decades of use ¹³.

Scheduled breaks also reduce cumulative immune-activation risk when Tα1 is combined with checkpoint inhibitors, given the single case of multisystem immune-related toxicity on that combination ²³. Common markers for an off-period include normalized lymphocyte subsets, a plateau in immune markers after 4-6 weeks, or completion of the planned course ³.

Tα1 is almost always studied as part of a combination, so its stacking profile is unusually well mapped compared with most peptides.

• With checkpoint inhibitors: the PRaG platform pairs Tα1 with PD-1 inhibitors, radiotherapy, and GM-CSF, producing responses in heavily pretreated cancers with no grade 3 or higher treatment-related events ³. Observational liver-cancer data show improved outcomes when Tα1 is added to anti-PD-1 therapy ¹⁶. The documented caution is sentinel monitoring for fever, rash, or breathing changes ²³.
• With chemotherapy: dacarbazine plus Tα1 outperformed control in phase 2 melanoma, with no added toxicity ¹⁴; a TNF-Tα1 fusion plus FOLFIRINOX produced 36.9% target-lesion regression in a case report ⁵⁵.
• With antivirals and antifungals: entecavir plus Tα1 improved complete-response rates in hepatitis B cirrhosis ⁵⁶; voriconazole plus Tα1 improved fungal clearance ²¹.
• In critical care: ulinastatin plus Tα1 is among the highest-ranked sepsis regimens for mortality in network meta-analysis ⁴.
• With omega-3: in severe acute pancreatitis, Tα1 plus intravenous fish-oil emulsion lowered inflammatory markers and infection rates more than omega-3 alone ⁵⁸.

Stacks to treat with caution

Thymosin Beta-4 exerts opposite effects on the mixed lymphocyte reaction, so the two thymic peptides are not stacked for immune endpoints ⁶¹. Tα1 suppresses pituitary TSH, ACTH, and prolactin release when given centrally in rats, so growth-hormone secretagogues and thyroid or adrenal therapies deserve endocrine monitoring ⁵³. BPC-157 is commonly co-administered in community practice for tissue-repair purposes without reported conflict, though no published interaction data exist.

Thymosin Alpha-1 (thymalfasin, Zadaxin) is registered in multiple countries for chronic hepatitis B and as a vaccine-response enhancer in immunocompromised patients, but it holds no FDA marketing authorization in the United States ¹¹. Historical US use ran through physician-sponsored INDs and large phase 3 trials rather than an approved label ¹³.

• China is the most permissive jurisdiction: Tα1 is an approved immunomodulator widely used in hepatitis B, cancer, and severe infection, and a 2025 expert consensus standardized its use across infectious and critical-care indications ¹.
• US access proceeds through 503A/503B compounding pharmacies under prescriber order rather than through FDA approval. Tα1 is not a controlled substance and appears on no DEA schedule.
• Europe, UK, and Australia: there is no centralized EMA authorization; Zadaxin has been marketed in Italy, where phase 3 development occurred ¹³. It is not licensed by the MHRA or registered with the TGA.

Sports and anti-doping

Tα1 is not on the WADA Prohibited List and holds governmental approval in several jurisdictions. No athlete sanctions are documented. This contrasts with Thymosin Beta-4, which anti-doping bodies do target.

The evidence regulators weigh is summarized in the Cochrane 2026 review, with low to very low certainty for mortality reduction in hepatitis B ², alongside favorable human safety reviews ¹⁰.

Across decades of trials, Tα1 has one of the most benign side-effect profiles in the peptide literature, with adverse-event rates in controlled trials often numerically lower than placebo ¹⁰.

Common effects

• Injection-site reactions: redness, pain, or firmness at subcutaneous sites are the most frequently reported complaints and are managed by site rotation.
• Transient flu-like symptoms: low-grade fever, fatigue, or mild headache in the first one to two weeks, typically resolving without stopping treatment.
• Early immune shifts: mild transient rises in lymphocytes or cytokines can occur as the intended pharmacodynamic effect rather than a reaction ²⁶.

What controlled trials show

• Sepsis meta-analysis of 1,972 patients: Tα1 reduced 28-day mortality with no safety penalty ⁵.
• Phase 3 Reset-α: treatment-emergent adverse events in 48.4% of the Tα1 arm versus 72.1% for placebo ⁶.
• Cochrane hepatitis B review: fewer serious adverse events with Tα1 than control (RR 0.72) ².
• PRaG 5.0 cancer trial: no grade 3 or higher treatment-related events ³.
• A 39-trial COPD meta-analysis reported no safety signal ⁹.

Rare and theoretical concerns

A single case of multisystem immune-related toxicity (fever, rash, pulmonary edema, multi-organ failure) occurred during combination with the PD-1 inhibitor sintilimab; causality for Tα1 was not established ²³. Immune overactivation is therefore most plausible in checkpoint-inhibitor combinations rather than monotherapy ¹.

Theoretical cautions without clinical confirmation include autoimmune-flare risk from Th1 polarization ¹, effects on sleep-wake signaling through the orexin receptor ²⁵, and pituitary hormone shifts seen only with central administration in rats ⁵³. Rat studies show inhibition of both arms of the blood-coagulation pathway, with no human bleeding events reported ⁵¹.

Where caution is documented

Severe COVID-19 cohorts returned conflicting signals: one multicenter cohort linked Tα1 to worse recovery, especially with late initiation or high SOFA scores ³¹, while another showed a mortality benefit in patients with documented lymphopenia ³⁰. Benefit appears most reliable when treatment targets measured immune deficiency early in the course ¹⁸. No pregnancy, lactation, or pediatric safety data exist ².